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920 LETTERS TO THE EDITORfrom the CHS2 for parental stress measures. L.A.FANS did not
use validated stress measures; therefore, we chose psychoso-
cial stressors that pertain to the adolescent’s physical sur-
roundings or family functioning that have previously been
associated either with a stress response or with reduced lung
function (for detailed discussion of selected stressors, see the
Discussion section in this article’s Online Repository at
www.jacionline.org). Psychosocial stressors, which often clus-
ter in economically deprived neighborhoods, may explain
some of the adverse effects on respiratory health observed
with measures of socioeconomic status.5 The biologic under-
pinnings for synergisms between air pollution and stress on
lung function may be found in the immune response and in-
flammatory reactions.6,7 Many air pollutants consist of free
radicals, which in the lung tissue result in oxidative stress
that generates an inflammatory response, releasing additional
free radicals that ultimately damage lung tissue.6 Psychosocial
stressors, acting through the hypothalamic-pituitary-adrenal
axis modifications, also heighten inflammatory activity and
modulate immune function,8 potentially increasing susceptibil-
ity to environmental insults. This pathway may contribute to
some of the differential pulmonary vulnerability to air pollut-
ants observed in those with higher levels of psychosocial
stress.2
Briefly, strengths of our study include the use of adolescent
self-reported psychosocial stressors. In addition, our spirometry
estimates were sensitive to the effects of air pollution and both
measures were similar to estimates obtained for air pollutants
and pulmonary function from the CHS.9 However, validated or
more psychometrically sound instruments would have been
preferential to the stress measures that we used. Although we
chose psychosocial stressors based on empirical evidence of
cortisol activity in other research, without such biomarkers,
we do not know whether reported psychosocial stressors
caused a stress response in the adolescent. Our findings of
paternal absence are difficult to interpret, as the adolescents
were not further queried about their own feelings about the
familial composition or related stress. In addition, our sample
size did not allow us to analyze pulmonary function as a
change from predicted value from a standard population, nor
was our sample size large enough to calculate our own
standard reference. Thus, we have reported absolute changes
in pulmonary function values.
Healthy growth and development of pulmonary function in
childhood and adolescence is instrumental for respiratory health
in adulthood. Our findings contribute modest evidence to the
hypothesis that psychosocial stress modifies the effects of air
pollutants on lung function, and we hope they may inspire
researchers to measure stress when conducting research on
respiratory health.
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http://dx.doi.org/10.1016/j.jaci.2016.04.012Specific T cells for the treatment of
cytomegalovirus and/or adenovirus
in the context of hematopoietic
stem cell transplantationTo the Editor:
Viral infections following allogeneic hematopoietic stem cell
transplantation (HSCT) are associated with elevated morbidity
and mortality rates because HSCT exposes patients to a transient
state of profound T- and B-cell immunodeficiency. Most post-
HSCT viral infections are caused by the endogenous reactivation
of opportunistic pathogens such as adenovirus (ADV), cytomeg-
alovirus (CMV), and EBV.1 The risk of mortality associated with
these viral infections is directly proportional to (1) the degree of
HLA mismatch between the donor and the recipient and (2) the
time of T-cell reconstitution. Hence, this risk is lower in patients
with T-cell–repleted graft versus patients receiving T-cell–
depleted transplant.2 During the posttransplant period, several
prophylactic or preemptive antiviral treatments may be partially
effective by inhibiting viral replication and thus stabilizing the
viral load.3,4 However, antiviral drugs can also induce drug resis-
tance and be responsible for organ toxicity.5
Because the transfer of donor memory T lymphocytes directed
specifically against immunodominant viral antigens has been
shown to control ongoing viral infections, we designed a French
TABLE I. Patients’ characteristics
Patient Age (y)/sex Diagnosis Donor (MM) GvHD grade* GvHD treatment
Days between HSCT
and first injection
CD3/mL before
T-cell injection
P1 3/F FLH Mother
(3/6)
II Steroids 0.5 mg/kg/d
aR-IL2
46 NA
P2 1.08/M SCID T2B1NK1 Father
(3/6)
— 105 127
P3 2/F LH Mother
(3/6)
— 182 1066
P4 46/M Blastic CML Sibling donor
(10/10)
II Steroids 0.4 mg/kg/d 128 73
P5 2/F AA Sibling donor
(10/10)
— 97 109
P6 0.66/F FLH MUD
(10/10)
— 78 24
P7 52/M CLL Sibling donor
(10/10)
II Steroids 0.4 mg/kg/d
CsA 150 mg/d
286 1831
P8 0.50/M FLH Mother
(2/6)
— 29 0
P9 56/M AA MUD
(10/10)
— 87 80
P10 33/M AA Sibling donor
(10/10)
— 117 324
P11 63/F HL MUD
(10/10)
I Steroids 1 mg/kg/d
CsA 100 mg/d
58 174
P12 1.33/M CID MUD
(10/10)
I Steroids 0.5 mg/kg/d
MMF 270 mg/d
74 708
P13 58/M IAL MUD
(9/10)
— 370 2300
P14 24/F AML MUD
(9/10)
— 160 378
P15 1.66/F AA Mother
(3/6)
— 48 0
All the HLA-partially mismatched grafts from related donors were T-cell–depleted by CD341 immunoselection.
AA, Aplastic anemia; AML, acute myeloid leukemia; CID, combined immunodeficiency; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; CsA, cyclosporine A;
F, female; FLH, familial lymphohistiocytosis; HL, Hodgkin lymphoma; IAL, immunoangioblastic lymphoma; M, male; MM, mismatch; MMF, mycophenolate mofetyl; MUD,
matched unrelated donor; NA, not available; P, patient; SCID, severe combined immunodeficiency.
*Grade at the time of T-cell injection. The treatment is described in the next column.
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the aim of treating pediatric or adult recipients of allogeneic
HSCT (regardless of the underlying disease).6-8 Inclusion criteria
were as follow: (1) donor chimerism 10%ormore at inclusion; (2)
biological signs of infection with CMVwith resistance or intoler-
ance to conventional antiviral treatments, or CMVorADVdisease
with documented organ damage; (3) graft versus host activity
(<_II) controlled by corticoids (<1 mg/kg) at the time of inclusion;
and (4) donor with positive CMV and/or ADV serology. Donor
mononuclear cells were obtained by leukapheresis and were stim-
ulated with Peptivator pp65 CMV antigen or PepAdV5 Hexon
ADV antigen (both from Miltenyi Biotech, Bergisch Gladbach,
Germany) for 4 and 6 hours, respectively. Magnetic enrichment
of IFN-g–secreting cells was performed with the Cytokine
Secretion System and the CliniMACS device (Miltenyi Biotech).
This rapid (<24 hours) and HLA-independent procedure for
immunoselection has been described elsewhere in detail.9
The virus-specific T cells (release criteria >_ 10% IFN-g1
T cells) were infused immediately after the isolation procedure.
This study was approved by the local institutional review board
(CPP 2010-01-04) and the Agence Nationale de Securite du
Medicament (reference TC271).
Between September 2010 and September 2013, 16 allogeneic
HSCT recipients (8 adults and 8 infants) infected with CMV(n5 7), ADV (n5 5), or both (n5 3) were enrolled by 7 French
hospitals. One CMV-infected adult withdrew his consent before
treatment and was excluded from the analyses. Characteristics of
treated patients are detailed in Tables I and II. Characteristics of
the cell products infused are detailed in Tables E1 and E2 in
this article’s Online Repository at www.jacionline.org. In the
CMV group, patients received 1 (n 5 4), 2 (n 5 5), or 3
(n 5 1) anti-CMV T-cell infusions. In the ADV group, patients
received 1 (n5 5), 2 (n 5 2), or 3 (n5 1) anti-ADV T-cell infu-
sions (Table E1). The median (range) time between HSCTand T-
cell injection was 100.5 days (29-370 days) for patients with
CMV infections and 73 days (29-159 days) for patients with
ADV infections. The median (range) number of injected anti-
CMV and anti-ADV CD3/IFN-g1 cells per kg body weight
were 3,540 (1,640-19,900) and 3,739.5 (807-10,800),
respectively.
Among the 10 patients with CMVinfection, patient 6 died from
alveolar hemorrhage before the day121 evaluation. Patients 2, 3,
and 7 showed a complete virological response after 1 (n5 2) or 2
(n 5 1) infusions. This response was associated with in vivo
expansion of CMV-specific T lymphocytes as IFN-g–producing
T cells and pentamer1 CD81 T cells increased from 5.8/mL (0-
13.9) (n 5 7) and 1.2/mL (0-2.8) (n 5 4) on the day of infusion
to 20.58/mL (0.16-49.1) and 3.2/mL (0.4-7.6) at day121,
TABLE II. Follow-up and outcomes of patients after the adoptive transfer of CMV- and ADV-specific T cells
Patient Infection
Viral load at
day10 (log/mL)
Viral load at
day121 (log/mL)
GvHD grade
at day121
CD31 specific T-cell
expansion at day121
Clinical outcome 6 mo
after the first injection/
cause of death
CMV-infected patients
P2 Meningoencephalitis
Retinitis
2.5 <threshold None Yes Alive with stabilization of
retinitis
P3 Diarrhea
Retinitis
Blood replication
4.2 <threshold None Yes Alive with stabilization of
retinitis
P5 Blood replication 2.4 3.3 None No Alive/death at day1186/viral
cardiorespiratory failure
P6* Pneumopathy
Encephalitis
Retintis
Blood replication
3.7 NA NA NA Death at day13/alveolar
hemorrhage
P7 Blood replication 2.3 4.3 None Yes Alive with extensive cGvHD
P8 Blood replication 5.8 5.7 None No Death at day196/pulmonary
arterial hypertension
P10 Pneumopathy
Blood replication
3.8 4.1 Grade III Yes Death at day197/ADV
pneumonitis
P12 CMV retinitis 4.5 NA None Yes Alive and blind
P13 Blood replication 3.6 4.1 None Yes Alive and well
P15 Diarrhea 5.8 6.5 None No Death at day130/disseminated
ADV and CMV infection
ADV-infected patients
P1 Meningoencephalitis
Retinitis
2.5 <threshold None Yes Alive with stabilization of
retinitis
P4 Diarrhea
Retinitis
Blood replication
4.2 P < threshold None Yes Alive with stabilization of
retinitis
P5 Blood replication 2.4 3.3 None No Alive/death at day1186/viral
cardiorespiratory failure
P8 Pneumopathy
Encephalitis
Retintis
Blood replication
3.7 NA NA NA Death at day13/alveolar
hemorrhage
P9 Blood replication 2.3 4.3 None Yes Alive
P11 Blood replication 5.8 5.7 None No Death at day125/alveolar
hemorrhage
P14 Pneumopathy
Blood replication
5.4 Positive
<threshold
None Yes Death at day133/PTLD
P15 Diarrhea
Blood replication
5.8 NA NA NA Death at day130/disseminated
ADV and CMV infection
Threshold of detection was 500 copies of infectious genome per milliliter for ADV and CMV quantitative PCR.
CGvHD, Chronic graft versus host disease; NA, not available; P, patient; PTLD, posttransplant lymphoproliferative disease.
*P6 died 3 days after adoptive transfer.
P9 died 14 days after adoptive transfer.
P15 died 3 days after adoptive transfer.
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plete remission of CMV encephalitis in patient 2 (Fig 1, A).
Five patients did not display any significant changes in CMV viral
load at day121. The lack of in vivo CMV-specific T-cell expan-
sion at day 21 was always associated with the absence of an
anti-CMV response. Clinical evaluation 6months after the last in-
jection showed that only 1 patient among 3 (patient 15) had died
from a CMV-related disease (Table II).
Among the 8 patients with ADV infection, patients 9 and 15
died before the day121 evaluation. Of the remaining 5 patients, 3
showed a complete virological response at day121, 1 a partial
response (that became complete at day147), and 1 no response.Two of the 4 patients with virological response (patients 4 and 14)
also displayed ADV-specific T-lymphocytes expansion. The
clinical outcome was unfavorable in all but 1 patient with ADV
but only 1 of the deaths was related to ADV (patient 1) (Table II).
A total of 9 severe adverse events (SAEs) occurred in 6 patients
and were classified as having a possible link with T-cell infusion.
Four ADV-infected patients experienced worsening of respiratory
symptoms or liver cytolysis that could be related to the natural
course of the infection, another viral infection, or a proper T-cell
infusion effect. Two patients presented with apparent septic shock
following the infusion while the microbiological testing result of
the T-cell product was negative. Other SAEs were grade III graft
FIG 1. Evolution of viral load and circulating CD4 and CD8 IFN-g1 T-cell counts after antiviral adoptive
therapy in patient 7 (A) and patient 2 (B). In patient 7, the regression of the viral load was concomitant with a
significant and intentional reduction of corticosteroids to 5 mg (total dose), whereas the viral reactivation at
d1100 was concomitant to a worsening of chronic graft versus host disease requiring corticosteroids
additional increase up to 0.5 mg/kg. *Viral load at day 100 was measured by the local laboratory but was
not recorded in the study database. CSF, Cerebrospinal fluid.
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hematemesis (n5 1) (see Table E3 in this article’s Online Repos-
itory at www.jacionline.org).
Despite the relatively low number of patients included, this
study shows that rapidly prepared CMV- and/or ADV-specific
T cells seem efficient in a subset of HSCT recipients with severe
viral infections as one-third of the patients showed a complete
virological response in parallel with specific T-cell expansion
even in the presence of significant corticotherapy. The cell
infusion seems to be safe despite the difficulty in accurately
assessing SAEs in an observational study of patients with
extremely poor condition at inclusion. However, larger studies
are needed to assess clinical and biological parameters associated
with treatment failure and efficacy. Moreover, as timing anddosage of the treatment might have a major influence on efficacy,
future works should investigate the optimal timing of infusion
—with consideration with preemptive therapy—and the optimal
cell dose to infuse—with regard to the risk of graft versus host
disease induction.
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http://dx.doi.org/10.1016/j.jaci.2016.03.032A combination of dexamethasone
and anti–IL-17A treatment can
alleviate diesel exhaust particle–
induced steroid insensitive asthmaTo the Editor:
A recent comprehensive and systematic review of worldwide
traffic emissions and health science by a special panel convened
by the Health Effects Institute found sufficient evidence that
exposure to traffic-related air pollution (TRAP) causes asthma
exacerbation in children.1 Diesel exhaust particles (DEPs) repre-
sent the major component of TRAP particulate matter and the
main contributor to TRAP-related asthma exacerbations in chil-
dren. We have previously shown that in children with allergic
asthma, TRAP exposure is associated with earlier sensitization,
and increased asthma prevalence and severity.2,3 Asthma severity,
defined as more frequent weekly symptoms, was associated with
increased IL-17A but not IL-4, IL-5, or IL-13 blood levels.2
Indeed, although asthma has long been described as a disease re-
sulting from an abnormal TH2 immune response to environmental
allergens, accumulating evidence suggests a role for TH17 cells,
especially in severe asthma.4 A recent study demonstrated that
dual-positive TH2/TH17 cells and IL-17Awere present at a higher
frequency in the bronchoalveolar lavage fluid (BALF) of patients
with severe asthma.5 Furthermore, the study found that these TH2/
TH17 cells were resistant to dexamethasone-induced cell death.
We recently reported that DEP coexposure augmented allergen-
induced airway hyperresponsiveness (AHR), eosinophilia, and
TH2 and TH17 cytokines levels, and resulted in increased numbers
of TH2/TH17 cells in the BALF.
2 Collectively, these data suggest
that a subgroup of patients with asthma with high DEP exposure
and mixed TH2/TH17 responses may benefit from anti–IL-17A
therapy alone or in combination with steroids. Although inhibi-
tion of IL-17 receptor A did not result in significant improvement
among subjects with moderate to severe asthma in a recent ran-
domized controlled trial,6 targeted anti–IL-17 therapy in a subset
TABLE E1. Characteristics of CMV-specific T cells
Patient
No. of
procedures
No. of
infusions
% of IFN-g1 cells/
CD31 lymphocytes
CD41IFN-g1
count (104)
CD81IFN-g1
count (104)
Yield of IFN-g1
CD41 T cell (%)
Yield of IFN-g1
CD81 T cell (%)
Dose of IFN-g1
CD31/kg
P2 1 2 23.8 15.00 28.00 54 85 5,113
4,938
P3 1 2 92.5 16.00 112.00 70 80 5,000
5,000
P5 1 1 22.4 0.79 0.76 19 35 2,280
P6 1 1 18 0.98 0.39 0.9 1 1,760
P7 1 2 95.8 110.00 3.24 18 4 5,428
15,100
P8 1 3 93.3 34.80 219.00 46 49 3,030
5,880
19,900
P10 1 1 96.4 12.40 83.80 16 15 1,640
P12 1 1 96.1 0.39 4.99 2.4 12 4,950
P13 1 1 86.4 8.60 37.60 22 30 4,800
2 1 85.4 6.36 31.80 48 55 5,127
P15 1 2 96.3 41.20 250.00 72 83 5,000
5,000
Median 92.50 12.40 31.80 22.00 35.00 3,540.00
P, Patient.
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TABLE E2. Characteristics of ADV-specific T cells
Patient
No. of
procedures
No. of
infusions
% of IFN-g1 cells/
CD31 lymphocytes
CD41IFN-g1
count (104)
CD81IFN-g1
count (104)
Yield of IFN-g1
CD41 T cell (%)
Yield of IFN-g1
CD81 T cell (%)
Dose of IFN-g1
CD31/kg
P1 1 2 33.5 7.81 8.20 4 5 5,000
1,546
P4 1 1 59 17.15 38.66 13 14 3,979
P5 1 1 39 0.52 0.22 0.6 0.3 1,167
2 1 28 1.31 0.93 7 5 3,298
3 1 18.6 7.67 5.89 31 23 10,800
P8 1 2 89.7 46.50 63.80 83 12 2,970
5,210
P9 1 1 77.4 14.70 16.80 166 82 3,500
P11 1 1 79.7 0.66 0.68 5 4 807
P14 1 1 80.4 28.00 93.80 73 88 5,140
P16 1 1 63.8 3.15 9.30 42 47 5,000
Median 61.40 7.74 8.75 22.00 13.00 3,739.50
P, Patient.
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TABLE E3. Serious adverse event observed in treated patients
Patient SAE
Delay between SAE and
specific T-cell infusion
P1 Multivisceral failure due
to disseminated CMV
infection
Death
Day17
Day131
P2 None NA
P3 None NA
P4 Sepsis Day11
P5 Worsening respiratory
symptoms
5 mo
P6 Alveolar hemorrhage and
death
Day13
P7 Gram-negative sepsis Day112
P8 Pulmonary hypertension
and intraalveolar
hemorrhage
Death
Day136
Day196
P9 Multivisceral failure
Death
Day110
Day114
P10 Stage III GvHD
Death from ADV
pneumonitis
Day15
Day197
P11 Intraalveolar hemorrhage,
hematemesis
Death
Day114
Day125
P12 None NA
P13 Sepsis
Pneumopathy
Day123
Day148
P14 Respiratory distress
Death from PTLD
Day120
Day133
P15 Acute respiratory distress
syndrome due to CMV
and ADV and death
Day13
GvHD, Graft versus host disease; NA, not applicable; P, patient; PTLD, posttransplant
lymphoproliferative disease.
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